巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Aytu BioPharma

    AYTU
    0.520
    0.010
    1.89%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Aytu BioPharma - 延遲價格・最後更新於 24/06 12:15
    最高位
    0.539
    最低位
    0.511
    開市價
    --
    前收市價
    0.530
    成交量(千)
    8.72
    成交額(百萬)
    0.04
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    20.06
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    5.580 - 0.450
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Aytu BioScience
    證券代碼
    AYTU.US
    所屬板塊
    Drug Manufacturers - Specialty & Generic
    公司業務
    Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA.
    發行量
    38574875
    公司總部
    373 Inverness Parkway, Suite 206
    公司網址
    https://www.aytubio.com
    公司電郵
    info@aytubio.com
    公司電話
    +1 720 437-6580
    暫無內容

    關於

    Aytu BioPharma(AYTU.US)所屬的行業板塊為Drug Manufacturers - Specialty & Generic。
    Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA.
    詳細公司背景可參考: https://www.aytubio.com